Overview

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (KOV-HIPEC-04)

Status:
Not yet recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Center, Korea
Treatments:
Cisplatin